These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. McLaren CE; Fujikawa-Brooks S; Chen WP; Gillen DL; Pelot D; Gerner EW; Meyskens FL Cancer Prev Res (Phila); 2008 Dec; 1(7):514-21. PubMed ID: 19139001 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. Meyskens FL; Kingsley EM; Glattke T; Loescher L; Booth A Invest New Drugs; 1986; 4(3):257-62. PubMed ID: 3102397 [TBL] [Abstract][Full Text] [Related]
5. Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions. Doyle KJ; McLaren CE; Shanks JE; Galus CM; Meyskens FL Arch Otolaryngol Head Neck Surg; 2001 May; 127(5):553-8. PubMed ID: 11346432 [TBL] [Abstract][Full Text] [Related]
12. Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients. Talpaz M; Plager C; Quesada J; Benjamin R; Kantarjian H; Gutterman J Eur J Cancer Clin Oncol; 1986 Jun; 22(6):685-9. PubMed ID: 3091371 [TBL] [Abstract][Full Text] [Related]
13. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Loprinzi CL; Messing EM; O'Fallon JR; Poon MA; Love RR; Quella SK; Trump DL; Morton RF; Novotny P Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):371-4. PubMed ID: 9162303 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans. Creaven PJ; Pendyala L; Petrelli NJ Cancer Epidemiol Biomarkers Prev; 1993; 2(3):243-7. PubMed ID: 8318877 [TBL] [Abstract][Full Text] [Related]
15. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Waters GS; Ahmad M; Katsarkas A; Stanimir G; McKay J Ear Hear; 1991 Apr; 12(2):91-102. PubMed ID: 2065844 [TBL] [Abstract][Full Text] [Related]
16. A phase I study of hepatic arterial infusion using difluoromethylornithine. Lipton A; Harvey HA; Glenn J; Weidner WA; Strauss M; Miller SE; Taylor JB; White-Hershey D; Barlow JL Cancer; 1989 Feb; 63(3):433-7. PubMed ID: 2492203 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of alpha-difluoromethylornithine and methyl-GAG. Splinter TA; Romijn JC Eur J Cancer Clin Oncol; 1986 Jan; 22(1):61-7. PubMed ID: 3082642 [TBL] [Abstract][Full Text] [Related]
18. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233 [TBL] [Abstract][Full Text] [Related]
19. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. Meyskens FL; Emerson SS; Pelot D; Meshkinpour H; Shassetz LR; Einspahr J; Alberts DS; Gerner EW J Natl Cancer Inst; 1994 Aug; 86(15):1122-30. PubMed ID: 8028034 [TBL] [Abstract][Full Text] [Related]